Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK424887 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Citalopram | ACTIVE_COMPARATOR | Marketed comparitor |
| Investigational Medicinal Product | EXPERIMENTAL | GSK424887 |
| Placebo To Match Treatment | PLACEBO_COMPARATOR | Placebo control |
| Active | EXPERIMENTAL | GSK424887 once daily |
| Placebo | PLACEBO_COMPARATOR | Placebo once daily |
| Name | Type | Description |
|---|---|---|
| Citalopram | DRUG | Neurophysiological testing. |
| GSK424887 | DRUG | Neurophysiological testing |
| Plactebo To Match | DRUG | Neurophysiological testing |
| Placebo | DRUG | Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule |
| PET | RADIATION | Each subject will undergo 3 PET scans : one at Baseline and the others following dosing with GSK424887 at approximately 2h post-dose and aproximately 24 hours post-dose |
Inclusion Criteria: 1. Healthy males with no neurological, or history of psychiatric illness 2. Aged between 18 and 45 years 3. Agree to use contraception 4. BMI range of 18 to 33 kg/m² 5. Fluent English speakers 6. Non smoker or light smoker Exclusion Criteria: 1. Positive pre-study drug/alcohol...
GSK424887 is an investigational small molecule being developed for depressive disorder and anxiety disorders. It is in Phase 1 clinical development and has been studied in healthy volunteers in the United Kingdom. The drug is not approved and remains in early-stage clinical testing.
GSK424887 is being developed by GSK plc, a biopharmaceutical company traded on the New York Stock Exchange under the ticker GSK. The company has conducted Phase 1 clinical trials of the drug in the United Kingdom.
GSK424887 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving healthy volunteers. The drug is investigational and has not been approved for any use.
GSK424887 has been studied in two completed Phase 1 trials. NCT01059591 was a first-in-human study with 26 participants, and NCT01424384 examined emotional processing in healthy volunteers with 54 participants. Both trials were conducted in the United Kingdom and enrolled male participants aged 18 years and older.
GSK424887 is the investigational drug referred to in the clinical trial NCT01424384, which is titled 'Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic.' The drug is being studied for its potential effects in depressive disorder and anxiety disorders.